MedTrace Logo

Intralesional Versus Intramuscular Hepatitis B Vaccine Immunotherapy for Warts

NCT05326152 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-04-13

No results posted yet for this study

Summary

Assessment of the effectiveness of intralesional and intramuscular hepatitis B vaccine in treatment of multiple common warts.

Conditions

  • Intralesional Versus Intramuscular Hepatitis B Vaccine for Multiple Common Warts

Interventions

BIOLOGICAL

hepatitis B vaccine immunotherapy of common warts (GeneVac-B 10 ml vial, Serum Institute of India Ltd., Pune, India)

Randomized placebo-controlled comparative effectiveness clinical trial

BIOLOGICAL

Intralesional saline

Intralesional saline

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-06-20
Completion
2021-10-25

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05326152 on ClinicalTrials.gov